# Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

> **NCT05281614** · EARLY_PHASE1 · COMPLETED · sponsor: **Benaroya Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT05281614
- **Lead sponsor:** Benaroya Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-21
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-01-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281614, "Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05281614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*